Vaccines for Prevention and Reversal of Atherosclerosis

Inventors: Eva Gonczol and Klara Berencsi

Tech ID: GE-96002

Description: Infections with cytomegalovirus (CMV) or C. pneumoniae have been associated with atherosclerotic lesions and the subsequent development of coronary artery disease. Wistar scientists have demonstrated in animal models that vaccines against these pathogens may help prevent atherosclerosis in animals that have been previously infected with CMV or C. pneumoniae.

Key Words: Therapeutic, vaccine, cardiovascular, herpes virus, atherosclerosis

Applications and Advantages: This technology represents a new therapeutic use of vaccines for these agents.

Intellectual Property Status: US Patent 6,291,437, "Methods and compositions for retarding the development of atherosclerotic lesions" was issued September 18, 2001. PCT/US97/14443 has been published. Additional US patents and international patents in Europe, Canada, Japan, and Australia are pending.

Licensing Opportunity: These patents are available for exclusive license to a company that is developing vaccines for CMV and/or C. pneumoniae.

Contact:

Meryle J. Melnicoff
Director, Business Development
The Wistar Institute
3601 Spruce Street
Philadelphia, PA 19104
Phone: (215) 898-0049
Fax: (215) 573-2456
melnicoff@wistar.org

Last updated: Jul-02